Get the Stockscreener App
23.98
1.61%
0.3681
Immunome Inc stock is traded at $23.98, with a volume of 735.65K.
It is up +1.61% in the last 24 hours and up +29.12% over the past month.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
See More
Previous Close:
$23.61
Open:
$23.5
24h Volume:
735.65K
Relative Volume:
0.57
Market Cap:
$2.71B
Revenue:
$4.02M
Net Income/Loss:
$-224.59M
P/E Ratio:
-10.08
EPS:
-2.3795
Net Cash Flow:
$-205.52M
1W Performance:
+14.02%
1M Performance:
+29.12%
6M Performance:
+21.47%
1Y Performance:
+171.38%
1-Day Range:
$22.88
$24.14
1-Week Range:
$20.65
$24.14
52-Week Range:
$7.96
$27.65
Immunome Inc Stock (IMNM) Company Profile
Name
Immunome Inc
Sector
Industry
Phone
610-321-3700
Address
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
23.96 | 2.40B | 4.02M | -224.59M | -205.52M | -2.3795 |
VRTX
Vertex Pharmaceuticals Inc
|
528.26 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
647.63 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
926.39 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.74 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.28 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-26 | Initiated | H.C. Wainwright | Buy |
| Dec-01-25 | Initiated | Truist | Buy |
| Sep-22-25 | Initiated | Goldman | Buy |
| Sep-05-25 | Initiated | Craig Hallum | Buy |
| Apr-02-25 | Initiated | Lake Street | Buy |
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Apr-30-24 | Initiated | JP Morgan | Overweight |
| Apr-15-24 | Initiated | Guggenheim | Buy |
| Jan-29-24 | Initiated | Leerink Partners | Outperform |
| Dec-19-23 | Initiated | Wedbush | Outperform |
| Oct-29-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Immunome Inc Stock (IMNM) Latest News
Is Immunome’s (IMNM) Russell Exit Quietly Recasting Its Shareholder Base And Liquidity Story? - simplywall.st
Form 144 Immunome For: 30 June By Investing.com - Investing.com South Africa
[144] Immunome Inc. SEC Filing - Stock Titan
Immunome CMO Robert Lechleider sells $1.09m in stock - Investing.com
Form 4 Immunome Inc For: 29 June By Investing.com - Investing.com South Africa
Immunome CMO Robert Lechleider sells $1.09m in stock By Investing.com - Investing.com Canada
Immunome (IMNM) CMO sells 55K shares after exercising options - Stock Titan
Immunome Inc. (IMNM) Holds Steady Near Support Amid Low VolatilityStop Run - dars.gov.et
Immunome, Inc.(NasdaqCM:IMNM) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Immunome, Inc.(NasdaqCM: IMNM) dropped from Russell 3000E Index - marketscreener.com
Immunome, Inc.(NasdaqCM: IMNM) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Immunome, Inc.(NasdaqCM: IMNM) dropped from Russell Microcap Index - marketscreener.com
(IMNM) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Immunome, Inc. Actuals & Estimates (NASDAQ:IMNM) - TradingView
Form 144 Immunome Inc. For: 25 June By Investing.com - Investing.com South Africa
IMNM Forecast — Price Target — Prediction for 2027 - TradingView
Does Immunome's (IMNM) New IM-1617 Trial Reveal Its Real Antibody-Drug Conjugate Ambitions? - simplywall.st
A Quick Look at Today's Ratings for Immunome(IMNM.US), With a Forecast Between $33 to $40 - Moomoo
Immunome Stocklong-term pipeline and business model under review - AD HOC NEWS
Immunome Inc (IMNM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Immunome Inc (IMNM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Immunome Inc (IMNM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Immunome Inc (IMNM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Immunome Inc (IMNM) Institutional Confidence - TradingKey
Immunome Inc (IMNM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Immunome Inc (IMNM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Immunome Inc (IMNM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Immunome Inc (IMNM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immunome CFO Max Rosett sells $1.09m in stock By Investing.com - Investing.com Canada
Immunome CFO Max Rosett sells $1.09m in stock - Investing.com
Immunome (IMNM) CFO uses options, sells 60,000 shares under 10b5-1 plan - Stock Titan
(IMNM) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
How Immunome’s First-in-Human IM-1617 ADC Trial At Immunome (IMNM) Has Changed Its Investment Story - simplywall.st
IMNM (NASDAQ: IMNM) director plans to sell 60,000 shares via option - Stock Titan
Immunome (IMNM) director receives 9,897 stock options at $18.16 strike price - Stock Titan
[Form 4] Immunome Inc. Insider Trading Activity - Stock Titan
Immunome (IMNM) director granted stock options on 9,897 common shares - Stock Titan
Immunome | 4: Statement of changes in beneficial ownership of securities-Director Barchas Isaac - Moomoo
Immunome (IMNM) director-linked entity awarded 9,897 stock options at $18.16 strike - Stock Titan
Immunome (IMNM) director Carol Schafer receives grant of 9,897 stock options - Stock Titan
Immunome (IMNM) 2026 meeting: directors elected, pay and auditor votes pass - Stock Titan
IMNM Reiterated by Wedbush -- Price Target Maintained at $31 - GuruFocus
Craig-Hallum Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $36 - Moomoo
LifeSci Capital Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $40 - Moomoo
J.P. Morgan Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $39 - Moomoo
Immunome (IMNM) Begins First Phase 1 Trial for IM-1617 - GuruFocus
Immunome doses first patient in IM-1617 cancer therapy trial By Investing.com - Investing.com Australia
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors - BioSpace
Immunome doses first patient in IM-1617 cancer therapy trial - Investing.com
Immunome director Bienaime sells $203k, buys $204k in same-day trades - Investing.com India
Immunome director Bienaime sells $203k, buys $204k in same-day trades By Investing.com - Investing.com Australia
Immunome Inc Stock (IMNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunome Inc Stock (IMNM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Barchas Isaac | Director |
Jun 30 '26 |
Sale |
21.12 |
101,050 |
2,134,176 |
308,504 |
0.72%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):